iSiP develops AI and machine-learning technologies that integrate physical simulation to enhance the drug discovery process. The company aims to increase the efficiency of identifying and developing new drug candidates, addressing the lengthy and costly nature of traditional pharmaceutical research.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery is a lengthy and expensive process, often requiring significant time and resources to identify and develop viable drug candidates. Existing methods may lack the efficiency needed to rapidly advance potential treatments through the pipeline.
Solution
iSiP is developing an AI-driven platform that integrates physical simulation to accelerate and enhance the drug discovery process. The platform aims to improve the efficiency of identifying and developing new drug candidates by combining artificial intelligence with detailed physical modeling. This approach enables high-precision activity prediction for a wide range of compounds, even in the absence of reference compounds, as validated by cell-based assays. iSiP's technology can also generate novel hit compounds from protein 3D structures, facilitating the discovery of new scaffolds for challenging targets.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and drug discovery organizations seeking to improve the efficiency and success rate of their drug development pipelines.
Features
- AI-driven engine for high-precision activity prediction of drug candidates
- Physical simulation integration to enhance the accuracy of predictions
- Ability to predict activity for a wide range of compounds, including activity cliffs
- Technology to generate novel hit compounds from protein 3D structures
- Successful discovery of novel scaffolds for orphan GPCR "GPR17"
- AI peptide decomposition technology for hit creation in ion-channel targets